AURO LABORATORIES
|
AURO LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 3.92 | 4.56 | 11.52 | 6.51 | 7.06 |
| CEPS(Rs) | 5.64 | 6.20 | 13.18 | 8.15 | 8.68 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 54.87 | 50.58 | 45.86 | 34.49 | 27.94 |
| Tax Rate(%) | 29.13 | 26.57 | 31.66 | 28.13 | 27.51 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.30 | 9.09 | 20.72 | 14.32 | 14.94 |
| EBIT Margin(%) | 8.05 | 9.24 | 20.21 | 14.20 | 14.83 |
| Pre Tax Margin(%) | 6.51 | 7.62 | 19.36 | 12.88 | 12.96 |
| PAT Margin (%) | 4.62 | 5.59 | 13.23 | 9.26 | 9.40 |
| Cash Profit Margin (%) | 6.65 | 7.59 | 15.14 | 11.60 | 11.55 |
| Performance Ratios | |||||
| ROA(%) | 4.40 | 5.87 | 19.34 | 12.32 | 13.78 |
| ROE(%) | 7.43 | 9.47 | 28.67 | 20.84 | 28.95 |
| ROCE(%) | 9.92 | 12.20 | 38.88 | 24.80 | 29.12 |
| Asset Turnover(x) | 0.95 | 1.05 | 1.46 | 1.33 | 1.47 |
| Sales/Fixed Asset(x) | 2.08 | 2.05 | 2.25 | 1.85 | 2.13 |
| Working Capital/Sales(x) | 3.07 | 2.95 | 2.90 | 3.71 | 5.37 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.48 | 0.49 | 0.44 | 0.54 | 0.47 |
| Receivable days | 89.77 | 75.03 | 44.00 | 59.53 | 65.79 |
| Inventory Days | 55.24 | 24.40 | 22.23 | 30.99 | 18.96 |
| Payable days | 83.56 | 59.08 | 67.05 | 73.97 | 66.85 |
| Valuation Parameters | |||||
| PER(x) | 13.95 | 21.98 | 7.04 | 4.83 | 8.42 |
| PCE(x) | 9.68 | 16.19 | 6.15 | 3.86 | 6.85 |
| Price/Book(x) | 1.00 | 1.98 | 1.77 | 0.91 | 2.13 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.72 | 1.26 | 0.72 | 0.39 | 0.88 |
| EV/Core EBITDA(x) | 7.13 | 11.18 | 3.26 | 2.36 | 5.16 |
| EV/EBIT(x) | 8.93 | 13.59 | 3.57 | 2.74 | 5.91 |
| EV/CE(x) | 0.68 | 1.16 | 0.93 | 0.53 | 1.23 |
| M Cap / Sales | 0.64 | 1.23 | 0.93 | 0.45 | 0.79 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.99 | -6.24 | 23.89 | -6.48 | 14.78 |
| Core EBITDA Growth(%) | -6.71 | -52.35 | 65.67 | -8.91 | 15.71 |
| EBIT Growth(%) | -9.37 | -57.13 | 76.27 | -10.41 | 16.86 |
| PAT Growth(%) | -14.15 | -60.38 | 77.08 | -7.84 | 24.65 |
| EPS Growth(%) | -14.15 | -60.38 | 77.08 | -7.84 | 24.65 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.19 | 0.44 | 0.11 | 0.15 | 0.46 |
| Current Ratio(x) | 1.95 | 1.86 | 3.03 | 2.93 | 1.87 |
| Quick Ratio(x) | 1.30 | 1.64 | 2.75 | 2.26 | 1.53 |
| Interest Cover(x) | 5.23 | 5.69 | 23.92 | 10.76 | 7.95 |
| Total Debt/Mcap(x) | 0.19 | 0.22 | 0.06 | 0.16 | 0.22 |
Compare Financial Ratios of peers of AURO LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AURO LABORATORIES | ₹115.8 Cr | 6% | -9.2% | 179.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
AURO LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AURO LABORATORIES | 6% |
-9.2% |
179.9% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
